Abstract
THE parenteral iron preparation ‘Imferon’, containing 5 per cent iron and 20 per cent dextran, is frequently used intravenously as well as by the intramuscular route for the treatment of anaemia due to iron deficiency.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cox, J. S. G., Fitzmaurice, C., Moss, G. F., and Ricketts, C. R. (unpublished results).
Golberg, L., in Iron in Clinical Medicine, edit. by Wallerstein, R. O., and Mettier, S. R., 78 (Univ. California Press, Berkeley, 1958).
Fielding, J., and Smith, G. M., J. Clin. Path., 16, 12 (1963).
Golberg, L., in Iron in Clinical Medicine, edit. by Wallerstein, R. O., and Mettier, S. R., 80 (1958).
Pharmacology Department, Fisons Pharmaceuticals, Ltd. (unpublished results).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
COX, J., KING, R. & REYNOLDS, G. Valency Investigations of Iron Dextran (‘Imferon’). Nature 207, 1202–1203 (1965). https://doi.org/10.1038/2071202a0
Published:
Issue Date:
DOI: https://doi.org/10.1038/2071202a0
This article is cited by
-
Pigment epitheliopathy with serous detachment of the retina following intravenous iron dextran
Eye (1992)
-
Mössbauer spectroscopic study of the reductive decomposition of iron(III) complexes
Journal of Radioanalytical and Nuclear Chemistry Articles (1985)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.